Home Alzheimer’s Disease Patients With Pretreated SCLC Have Improved Outcomes When Apatinib is Added to...

Patients With Pretreated SCLC Have Improved Outcomes When Apatinib is Added to Chemo

Data from a prospective phase 2 study (NCT03547804) indicate promising efficacy and a tolerable safety profile of apatinib (Rivoceranib) combined with single-agent chemotherapy for the treatment of patients with advanced small cell lung cancer (SCLC) who had received prior therapy for their disease. These results were presented in a poster at the 2020 World Conference on Lung Cancer (WCLC) Singapore.

While it accounts for around 15% of all lung cancers, SCLC is an aggressive malignancy with unsatisfactory treatment options in the second-line setting and beyond, with a median progression-free survival (PFS) of less than 3 months, the authors noted in their data.

Given this and the lack of targeted drugs or new chemotherapeutic agents in the advanced SCLC space, investigators from The First Hospital of Jilin University, Changchun, China, evaluated the efficacy and safety of the tyrosine…

Continue Reading to the Source

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Most Popular

Toni Choueiri, MD, on What Multidisciplinary Stakeholders Should Know About CheckMate 9ER

Results from the phase 3 CheckMate 9ER trial (NCT03141177) presented at the American Society of Clinical Oncology (ASCO) 2021 Genitourinary Cancer Symposium revealed that...

Robert J. Motzer, MD, on the Rationale for the Phase 3 CheckMate 9ER Trial in Advanced RCC

Compared with sunitinib (Sutent), combination treatment with nivolumab and cabozantinib demonstrated improved efficacy and prolonged survival among patients with previously treated advanced renal cell...

PHERGain II Trial Launched to Examine Chemotherapy-Free Treatment for Patients With HER2+ Breast Cancer

A clinical trial to support the use of a chemotherapy-free therapeutic approach has been launched and will aim to demonstrate that this approach is...

FDA Grants Breakthrough Therapy Designation to Tipifarnib for Treatment of HRAS-Mutant HNSCC

The FDA has granted breakthrough therapy designation to the investigational drug tipifarnib for the treatment of patients with recurrent or metastatic HRAS-mutant head and...

Recent Comments